WallStreetZenWallStreetZen

NASDAQ: APRE
Aprea Therapeutics Inc Stock Ownership - Who owns Aprea Therapeutics?

Insider buying vs selling

Have Aprea Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Oren GiladPresident CEO2024-03-132,000$7.29
$14.58kBuy
John P. HamillSrVPCFOPrin Fin Acct Ofcr2024-03-131,010$7.29
$7.36kBuy
John B. Henneman IiiDirector2024-03-136,860$7.29
$50.01kBuy
Bernd R. SeizingerDirector2024-03-136,860$7.29
$50.01kBuy

1 of 1

APRE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when APRE insiders and whales buy or sell their stock.

APRE Shareholders

What type of owners hold Aprea Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Tryant LLC515.47%28,000,000$72.80MInsider
Thomas Banks246.53%13,391,146$34.82MInsider
Frank J. Hall88.03%4,781,889$12.43MInsider
David West Wilson53.84%2,924,726$7.60MInsider
Heidi A. Patterson49.49%2,688,221$6.99MInsider
Kdev Investments Ab36.68%1,992,586$5.18MInsider
Michael Reynolds36.45%1,980,040$5.15MInsider
Redmile Group LLC32.56%1,768,718$4.60MInsider
Aigh Capital Management LLC9.93%539,300$1.40MInstitution
Oren Gilad6.14%333,295$866.57kInsider

1 of 3

APRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APRE3.39%96.61%Net Buying
NKGN9.66%62.24%Net Buying
EDSA1.74%98.26%Net Buying
PMCB13.44%14.65%
MTNB56.56%43.44%

Aprea Therapeutics Stock Ownership FAQ

Who owns Aprea Therapeutics?

Aprea Therapeutics (NASDAQ: APRE) is owned by 38.35% institutional shareholders, 1,092.32% Aprea Therapeutics insiders, and 0.00% retail investors. Tryant LLC is the largest individual Aprea Therapeutics shareholder, owning 28.00M shares representing 515.47% of the company. Tryant LLC's Aprea Therapeutics shares are currently valued at $72.80M.

If you're new to stock investing, here's how to buy Aprea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.